ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Reduced decorin expression in the tumor stroma correlates with tumor proliferation and predicts poor prognosis in patients with I-IIIA non-small cell lung cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Integrated analysis reveals key circRNA-mediated regulatory axes related to prognosis and immune infiltration in lung adenocarcinoma.BMC medical genomics · 2025Article
- The importance of biglycan, decorin and TGF-1 levels in the diagnosis of non-small cell lung cancer.Cancer biomarkers : section A of Disease markers · 2025Article
- Predicting Ki-67 expression levels in non-small cell lung cancer using an explainable CT-based deep learning radiomics model.Frontiers in oncology · 2025Article
- The Tumor Stroma of Squamous Cell Carcinoma: A Complex Environment That Fuels Cancer Progression.Cancers · 2024Review
- Article
- Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target.Frontiers in immunology · 2024Review
- Radiomics nomogram for the prediction of Ki-67 index in advanced non-small cell lung cancer based on dual-phase enhanced computed tomography.Journal of cancer research and clinical oncology · 2023Article
- Plasma Levels of Decorin Increased in Patients during the Progression of Breast Cancer.Journal of clinical medicine · 2021Article
- Study on the expression profile and role of decorin in the progression of pancreatic cancer.Aging · 2021Article
- Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer.Communications biology · 2021Article
- While Urine and Plasma Decorin Remain Unchanged in Prostate Cancer, Prostatic Tissue Decorin Has a Prognostic Value.Iranian biomedical journal · 2020Article
- Analysis of the relationship between Ki-67 expression and chemotherapy and prognosis in advanced non-small cell lung cancer.Translational cancer research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decorin, chiefly synthesized by tumor stroma, is known as a tumor suppressor. However, the clinical and prognostic significance in lung cancer remained unclear. Here, decorin and Ki67 expression was detected by immunohistochemistry (IHC) in I-IIIA non-small cell lung cancer (NSCLC) tissues (n = 264) in comparison to adjacent normal tissues (n = 40). The relationship between the expression of decorin and clinical characteristics, as well as Ki67 index and prognosis, was analyzed. Decorin expression was decreased in both the stroma (P < 0.001) and the tumor cells (P = 0.038) in NSCLC specimens. There was the lowest stromal expression of decorin in patients with G3 adenocarcinoma and higher Ki67 index in the stromal decorin-negative group. The Kaplan-Meier survival analysis demonstrated that lack of decorin in the stroma was correlated with a shorter DFS and OS (P = 0.005 and P = 0.010, respectively), while there was no significant association between decorin expression in the tumor cells and outcome. Multivariate analysis showed that reduced expression of decorin in the stroma was an independent prognostic factor for poor outcome including DFS (HR = 5.685, 95 % CI 0.493-0.933; P = 0.017) and OS (HR = 6.579, 95 % CI 0.484-0.908; P = 0.010). Negative decorin in the stroma combined with high Ki67 index predicted poorer outcomes for I-IIIA NSCLC patients. Our results provide data on decorin expression in both the stroma and cancer cells in NSCLC and reveal that reduced expression of stromal decorin correlates with high Ki67 index and has prognostic significance for poor outcome in I-IIIA NSCLC. Our data suggest that evaluating stromal decorin expression might be useful in assessing the prognosis and malignant potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.